Kyntra Bio, Inc. (KYNB) Stock Price & Analysis
Kyntra Bio, Inc. (KYNB) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $1.56 (-13.33%), as of the Nov 20, 2026 trading session; market cap $6.32M.
Educational signal · not a buy or sell recommendation · How to read this
Kyntra Bio, Inc. · KYNB · NASDAQ
Kyntra Bio, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company focuses on innovative medicines for anemia, fibrotic disease, and cancer, leveraging hypoxia-inducible factor and connective tissue growth factor biology.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Kyntra Bio (KYNB)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality and a strained balance sheet, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Falling.
- quarterly revenue $1M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
Holding back: balance-sheet strain, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 32 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.56 | |
| Change on the day | -13.33% | |
| Market capitalisation | $6.32M | — |
| Price / earnings (trailing) | 0.24 | |
| Shares traded on the day | 37.4K |
Price & events
Other perspectives
Council score for Kyntra Bio (KYNB): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Kyntra Bio (KYNB), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Kyntra Bio, Inc. (KYNB) is listed on NASDAQ. It employs 34 people. In Q3 FY2025 it reported revenue of $1M and net income of $201M. The market values it at $6.32M.
What do the latest results show for Kyntra Bio (KYNB)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $1M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $1M | $201M | $49.61 (diluted) |
| Q4 FY2025 | $1M | -$14M | -$3.51 (diluted) |
| Q1 FY2026 | $4M | -$15M | -$3.76 (diluted) |
| Q2 FY2026 | -$1M | $12M | $2.96 (diluted) |
What are the financial strengths and risks for Kyntra Bio (KYNB)?
Short answer
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, weak price trend. The distress and quality screens read Piotroski F 4. Trailing ratios: ROA -38.9% · current ratio 1.16.
How does Kyntra Bio compare with its peers?
Short answer
Kyntra Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $438.82 Nov 19, 2026 | $237B | 84 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $166.53 Nov 19, 2026 | $207B | 72 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $133.72 Nov 20, 2026 | $330B | 69 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| Kyntra Bio (KYNB) — this page | $1.56 | $6.32M | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 9
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 0
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held KYNB in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported KYNB in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Kyntra Bio (KYNB)?
- Kyntra Bio (KYNB) Q3 2026 Earnings Call Transcript
- Analysts Adjust Price Targets for Kyntra Bio Following Recent Developments
- Kyntra Bio Reports Third Quarter 2026 Financial Results and Terminates FG-3246 Phase 2 Trial
- Oppenheimer Adjusts Kyntra Bio Price Target to $30 From $35, Maintains Outperform Rating
Common Questions About KYNB
These answers are editorial: 1 of these 9 answers is drawn from the KYNB research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for KYNB?
KYNB carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Kyntra Bio, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics.
Is KYNB a good stock to buy?
Stock Expert AI does not rate KYNB buy, sell or hold. Kyntra Bio, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the KYNB stock price today?
The last price recorded for Kyntra Bio, Inc. (KYNB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for KYNB?
The main risks for Kyntra Bio, Inc. include clinical trial failures, which could significantly impact the value of its drug candidates. Regulatory hurdles and delays could also impede the company's progress in bringing its products to market.
What are the key factors to evaluate for KYNB?
Kyntra Bio, Inc. (KYNB) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Strategic Partnerships and Collaborations: Kyntra Bio can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Not financial advice.
How frequently does KYNB data refresh on this page?
KYNB's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven KYNB's recent stock price performance?
Kyntra Bio, Inc. (KYNB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in HIF and CTGF biology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KYNB overvalued or undervalued right now?
The trailing P/E of Kyntra Bio, Inc. (KYNB) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of KYNB?
Fractional-share availability for Kyntra Bio, Inc. (KYNB) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 11 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com